Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares are trading lower Thursday afternoon after the lupus-focused drugmaker posted fourth quarter earnings and raised expectations for continued growth in 2026. Here’s what investors need to know.Aurinia Pharmaceuticals stock is feeling bearish pressure. What’s pressuring AUPH stock?Lupkynis Sales Drive Full-Year GrowthThe company reported fourth-quarter 2025 adjusted earnings of 26 cents a share, beating analysts' consensus of 22 cents and surging from one cent a ...